ITRM Iterum Therapeutics plc NASDAQ -66% intraday 30 Mar 2026: heavy volume

ITRM stock plunged to USD 0.0594 on NASDAQ intraday 30 Mar 2026, down 66.25% from the prior close on heavy volume. The drop came with 545,949,619 shares traded versus an average volume of 1,094,132, making Iterum Therapeutics plc one of the most active names in the market right now. We examine what drove the move, how fundamentals and technicals stack up, and what traders should watch next in the United States healthcare market.

ITRM stock: Intraday price action and volume

The immediate driver is the intraday sell-off from a previous close of USD 0.17600 to the current USD 0.0594, with a session low of USD 0.0568 and a high of USD 0.0950. Volume spikes to 545,949,619 against an average of 1,094,132 indicate outsized liquidation. The relative volume of 30.83 points to algorithmic and retail order flow forcing the price much lower during this NASDAQ session.

ITRM stock: Fundamentals and valuation

Iterum Therapeutics plc is a clinical-stage biotechnology company developing anti-infectives, listed on NASDAQ and headquartered in Ireland. Key metrics show an EPS of -0.72 and a market capitalization near USD 1,934,484.00. Price averages sit at 0.26 (50-day) and 0.59 (200-day), while the 52-week high and low are 1.50 and 0.02710 respectively. Valuation ratios are stretched or negative given losses: P/E is not meaningful and price-to-sales is roughly 5.15, reflecting small revenues and large enterprise value relative to sales.

ITRM stock: Technicals and short-term signals

Technical indicators show the stock is deeply oversold. RSI is 20.12, Williams %R at -94.24, and MACD near zero with a negative bias. Bollinger Bands range from 0.09 to 0.25, and the ATR is 0.03, signaling elevated percent moves on small nominal changes. Traders should note the huge one-day range and the momentum readings that typically precede short-lived bounces in penny-stock biotech names.

ITRM stock: Catalysts, earnings calendar and news flow

An earnings announcement is scheduled for 31 Mar 2026 (U.S. time). Upcoming clinical or regulatory updates on sulopenem remain primary catalysts. Recent market headlines showed heavy coverage of the price move Investing.com and an earnings note at MarketBeat. Expect volatility around the earnings release and any clinical-data statements.

Meyka AI rates ITRM with a score out of 100 and forecast

Meyka AI rates ITRM with a score out of 100: 69.67 / 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector and industry comparisons, financial growth, key metrics, analyst consensus, and forecast models. Meyka AI’s forecast model projects a 12‑month estimate of USD 0.40412, compared to the current price of USD 0.0594. That implies a model-based upside of approximately 580.27%, though forecasts are model-based projections and not guarantees.

ITRM stock: Risks and realistic price targets

Downside risks include continued dilution, negative operating cash flow, and adverse clinical or regulatory news. Key financial ratios: current ratio 2.13, cash per share 0.24, and EV/sales near 63.44 highlight capital structure strain for a small biotech. Realistic near-term price targets for traders and analysts could be: conservative USD 0.20, base USD 0.40, and optimistic USD 1.00, depending on upcoming earnings and clinical updates.

Final Thoughts

ITRM stock is trading as one of the most active names on NASDAQ intraday on 30 Mar 2026 after a 66.25% drop to USD 0.0594 and exceptionally high volume of 545,949,619 shares. Short-term technicals show oversold momentum that can prompt volatile bounces, but fundamentals remain weak with EPS of -0.72 and limited market cap. Meyka AI’s models project a 12-month figure of USD 0.40412, implying roughly 580.27% upside from USD 0.0594, but that projection is model-based and not guaranteed. For traders, the path depends on the near-term earnings release and any clinical updates; for investors, dilution risk and cash runway require careful monitoring. We use Meyka AI’s real-time tools to flag this as a high volatility situation and recommend position sizing and stop levels aligned with your risk tolerance.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.